메뉴 건너뛰기




Volumn 5, Issue 1, 2018, Pages 65-78

Side-effects associated with ketamine use in depression: a systematic review

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE; ANESTHETIC AGENT; ANTIDEPRESSANT AGENT;

EID: 85026314929     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(17)30272-9     Document Type: Review
Times cited : (391)

References (127)
  • 1
    • 84876101644 scopus 로고    scopus 로고
    • Depression fact sheet (No. 369)
    • (accessed June 28, 2016).
    • WHO. Depression fact sheet (No. 369). http://www.who.int/mediacentre/factsheets/fs369/en/, 2016 (accessed June 28, 2016).
    • (2016)
  • 2
    • 84876830344 scopus 로고    scopus 로고
    • Depression: a global public health concern
    • (accessed June 28, 2016).
    • WHO. Depression: a global public health concern. http://www.who.int/mental_health/management/depression/who_paper_depression_wfmh_2012.pdf, 2012 (accessed June 28, 2016).
    • (2012)
  • 3
    • 84857039429 scopus 로고    scopus 로고
    • Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review
    • Undurraga, J, Baldessarini, RJ, Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology 37 (2011), 851–862.
    • (2011) Neuropsychopharmacology , vol.37 , pp. 851-862
    • Undurraga, J.1    Baldessarini, R.J.2
  • 4
    • 84955262240 scopus 로고    scopus 로고
    • Is treatment-resistant depression a useful concept?
    • Malhi, GS, Byrow, Y, Is treatment-resistant depression a useful concept?. Evidence Based Mental Health 19 (2016), 1–3.
    • (2016) Evidence Based Mental Health , vol.19 , pp. 1-3
    • Malhi, G.S.1    Byrow, Y.2
  • 6
    • 0021277596 scopus 로고
    • Identification of true drug response to anti-depressants. Use of pattern analysis
    • Quitkin, F, Rabkin, J, Ross, D, Stewart, JW, Identification of true drug response to anti-depressants. Use of pattern analysis. Arch Gen Psychiatry 41 (1984), 782–786.
    • (1984) Arch Gen Psychiatry , vol.41 , pp. 782-786
    • Quitkin, F.1    Rabkin, J.2    Ross, D.3    Stewart, J.W.4
  • 7
    • 84892146092 scopus 로고    scopus 로고
    • Quality of reporting in systematic reviews of adverse events: systematic review
    • Zorzela, L, Golder, A, Liu, Y, Pilklington, K, Hartling, L, Joffe, A, Quality of reporting in systematic reviews of adverse events: systematic review. BMJ, 348, 2014, 7668.
    • (2014) BMJ , vol.348 , pp. 7668
    • Zorzela, L.1    Golder, A.2    Liu, Y.3    Pilklington, K.4    Hartling, L.5    Joffe, A.6
  • 8
    • 0033969685 scopus 로고    scopus 로고
    • Antidepressant effects of ketamine in depressed patients
    • Berman, RM, Cappiello, A, Anand, A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47 (2000), 351–354.
    • (2000) Biol Psychiatry , vol.47 , pp. 351-354
    • Berman, R.M.1    Cappiello, A.2    Anand, A.3
  • 9
    • 84966349654 scopus 로고    scopus 로고
    • Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis
    • Xu, Y, Hackett, M, Carter, G, et al. Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis. Int J Neuropsychopharmacol, 19, 2016, pyv124.
    • (2016) Int J Neuropsychopharmacol , vol.19 , pp. pyv124
    • Xu, Y.1    Hackett, M.2    Carter, G.3
  • 10
    • 71649098114 scopus 로고    scopus 로고
    • Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression
    • aan het Rot, M, Collins, KA, Murrough, JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 67 (2010), 139–145.
    • (2010) Biol Psychiatry , vol.67 , pp. 139-145
    • aan het Rot, M.1    Collins, K.A.2    Murrough, J.W.3
  • 11
    • 84880852239 scopus 로고    scopus 로고
    • Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial
    • Irwin, SA, Iglewicz, A, Nelesen, RA, et al. Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial. J Palliat Med 16 (2013), 958–965.
    • (2013) J Palliat Med , vol.16 , pp. 958-965
    • Irwin, S.A.1    Iglewicz, A.2    Nelesen, R.A.3
  • 12
    • 84880767967 scopus 로고    scopus 로고
    • Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression
    • Murrough, JW, Perez, AM, Pillemer, S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 74 (2013), 250–256.
    • (2013) Biol Psychiatry , vol.74 , pp. 250-256
    • Murrough, J.W.1    Perez, A.M.2    Pillemer, S.3
  • 13
    • 84876531468 scopus 로고    scopus 로고
    • Serial infusions of low-dose ketamine for major depression
    • Rasmussen, KG, Lineberry, TW, Galardy, CW, et al. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol 27 (2013), 444–450.
    • (2013) J Psychopharmacol , vol.27 , pp. 444-450
    • Rasmussen, K.G.1    Lineberry, T.W.2    Galardy, C.W.3
  • 14
    • 84898003445 scopus 로고    scopus 로고
    • Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic
    • Diamond, PR, Farmery, AD, Atkinson, S, et al. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol 28 (2014), 536–544.
    • (2014) J Psychopharmacol , vol.28 , pp. 536-544
    • Diamond, P.R.1    Farmery, A.D.2    Atkinson, S.3
  • 15
    • 84891852276 scopus 로고    scopus 로고
    • Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression
    • Shiroma, PR, Johns, B, Kuskowski, M, et al. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord 155 (2014), 123–129.
    • (2014) J Affect Disord , vol.155 , pp. 123-129
    • Shiroma, P.R.1    Johns, B.2    Kuskowski, M.3
  • 16
    • 84938935980 scopus 로고    scopus 로고
    • Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: a comparison of ketamine and ECT
    • Allen, AP, Naughton, M, Dowling, J, et al. Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: a comparison of ketamine and ECT. J Affect Disord 186 (2015), 306–311.
    • (2015) J Affect Disord , vol.186 , pp. 306-311
    • Allen, A.P.1    Naughton, M.2    Dowling, J.3
  • 17
    • 85008682134 scopus 로고    scopus 로고
    • Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation
    • Cusin, C, Ionescu, DF, Pavone, KJ, et al. Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation. Aust N Z J Psychiatry 51 (2016), 55–64.
    • (2016) Aust N Z J Psychiatry , vol.51 , pp. 55-64
    • Cusin, C.1    Ionescu, D.F.2    Pavone, K.J.3
  • 18
    • 33644772133 scopus 로고    scopus 로고
    • Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions
    • Correll, GE, Futter, GE, Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions. Pain Med 7 (2006), 92–95.
    • (2006) Pain Med , vol.7 , pp. 92-95
    • Correll, G.E.1    Futter, G.E.2
  • 19
    • 56749177533 scopus 로고    scopus 로고
    • Intravenous ketamine “burst” for refractory depression in a patient with advanced cancer
    • Stefanczyk-Sapieha, L, Oneschuk, D, Demas, M, Intravenous ketamine “burst” for refractory depression in a patient with advanced cancer. J Palliat Med 11 (2008), 1268–1271.
    • (2008) J Palliat Med , vol.11 , pp. 1268-1271
    • Stefanczyk-Sapieha, L.1    Oneschuk, D.2    Demas, M.3
  • 20
    • 68549092716 scopus 로고    scopus 로고
    • Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases
    • Paul, R, Schaaff, N, Padberg, F, Moller, HJ, Frodl, T, Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. World J Biol Psychiatry 10 (2009), 241–244.
    • (2009) World J Biol Psychiatry , vol.10 , pp. 241-244
    • Paul, R.1    Schaaff, N.2    Padberg, F.3    Moller, H.J.4    Frodl, T.5
  • 21
    • 76349084738 scopus 로고    scopus 로고
    • Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series
    • Paslakis, G, Gilles, M, Meyer-Lindenberg, A, Deuschle, M, Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series. Pharmacopsychiatry 43 (2010), 33–35.
    • (2010) Pharmacopsychiatry , vol.43 , pp. 33-35
    • Paslakis, G.1    Gilles, M.2    Meyer-Lindenberg, A.3    Deuschle, M.4
  • 22
    • 79953057998 scopus 로고    scopus 로고
    • A case of sustained remission following an acute course of ketamine in treatment-resistant depression
    • Murrough, JW, Perez, AM, Mathew, SJ, Charney, DS, A case of sustained remission following an acute course of ketamine in treatment-resistant depression. J Clin Psychiatry 72 (2011), 414–415.
    • (2011) J Clin Psychiatry , vol.72 , pp. 414-415
    • Murrough, J.W.1    Perez, A.M.2    Mathew, S.J.3    Charney, D.S.4
  • 23
    • 84864288609 scopus 로고    scopus 로고
    • On the safety and benefits of repeated intravenous injections of ketamine for depression
    • Blier, P, Zigman, D, Blier, J, On the safety and benefits of repeated intravenous injections of ketamine for depression. Biol Psychiatry 72 (2012), e11–e12.
    • (2012) Biol Psychiatry , vol.72 , pp. e11-e12
    • Blier, P.1    Zigman, D.2    Blier, J.3
  • 24
    • 84864807084 scopus 로고    scopus 로고
    • Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression
    • Cusin, C, Hilton, GQ, Nierengerg, AA, Fava, M, Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. Am J Psychiatry 169 (2012), 868–869.
    • (2012) Am J Psychiatry , vol.169 , pp. 868-869
    • Cusin, C.1    Hilton, G.Q.2    Nierengerg, A.A.3    Fava, M.4
  • 25
    • 84883324216 scopus 로고    scopus 로고
    • Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression
    • Lara, DR, Bisol, LW, Munari, LR, Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int J Neuropsychopharmacol 16 (2013), 2111–2117.
    • (2013) Int J Neuropsychopharmacol , vol.16 , pp. 2111-2117
    • Lara, D.R.1    Bisol, L.W.2    Munari, L.R.3
  • 26
    • 85040148133 scopus 로고    scopus 로고
    • Maintenance ketamine treatment produces long-term recovery from depression
    • (accessed Jan 11, 2017).
    • Messer, M, Haller, I, Maintenance ketamine treatment produces long-term recovery from depression. http://primarypsychiatry.com/maintenance-ketamine-treatment-produces-long-term-recovery-from-depression/, May 21, 2013 (accessed Jan 11, 2017).
    • (2013)
    • Messer, M.1    Haller, I.2
  • 27
    • 84888002513 scopus 로고    scopus 로고
    • Ketamine for treatment of therapy-resistant depression: a case study
    • (in German).
    • Segmiller, F, Frisse, D, Eser, D, Moller, HJ, Ruther, T, Schule, C, Ketamine for treatment of therapy-resistant depression: a case study. Nervenarzt 84 (2013), 854–855 (in German).
    • (2013) Nervenarzt , vol.84 , pp. 854-855
    • Segmiller, F.1    Frisse, D.2    Eser, D.3    Moller, H.J.4    Ruther, T.5    Schule, C.6
  • 28
    • 84885066566 scopus 로고    scopus 로고
    • Repeated S-ketamine infusions in therapy resistant depression: a case series
    • Segmiller, F, Ruther, T, Linhardt, A, et al. Repeated S-ketamine infusions in therapy resistant depression: a case series. J Clin Pharmacol 53 (2013), 996–998.
    • (2013) J Clin Pharmacol , vol.53 , pp. 996-998
    • Segmiller, F.1    Ruther, T.2    Linhardt, A.3
  • 29
    • 84875366335 scopus 로고    scopus 로고
    • A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression
    • Szymkowicz, SM, Finnegan, N, Dale, RM, A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression. J Affect Disord 147 (2013), 416–420.
    • (2013) J Affect Disord , vol.147 , pp. 416-420
    • Szymkowicz, S.M.1    Finnegan, N.2    Dale, R.M.3
  • 30
    • 84880467266 scopus 로고    scopus 로고
    • Case report: Long-term mood response to repeat dose intramuscular ketamine in a depressed patient with advanced cancer
    • Zanicotti, CG, Perez, D, Glue, P, Case report: Long-term mood response to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. J Palliat Med 16 (2013), 719–720.
    • (2013) J Palliat Med , vol.16 , pp. 719-720
    • Zanicotti, C.G.1    Perez, D.2    Glue, P.3
  • 31
    • 84904043755 scopus 로고    scopus 로고
    • Long-lasting effects of a single subcutaneous dose of ketamine for treating melancholic depression: a case report
    • Galvez, V, O'Keefe, E, Cotiga, L, et al. Long-lasting effects of a single subcutaneous dose of ketamine for treating melancholic depression: a case report. Biol Psychiatry 76 (2014), e1–e2.
    • (2014) Biol Psychiatry , vol.76 , pp. e1-e2
    • Galvez, V.1    O'Keefe, E.2    Cotiga, L.3
  • 32
    • 84894251759 scopus 로고    scopus 로고
    • Effectiveness of ketamine in depressed patients resistant to ECT or rTMS therapy
    • (in Polish).
    • Gosek, P, Chojnacka, M, Bienkowski, P, Swiecicki, L, Effectiveness of ketamine in depressed patients resistant to ECT or rTMS therapy. Psychiatr Pol 48 (2014), 49–58 (in Polish).
    • (2014) Psychiatr Pol , vol.48 , pp. 49-58
    • Gosek, P.1    Chojnacka, M.2    Bienkowski, P.3    Swiecicki, L.4
  • 33
    • 84941884143 scopus 로고    scopus 로고
    • Augmentation therapy with serial intravenous ketamine over 18 months in a patient with treatment resistant depression
    • Hassamal, S, Spivey, M, Pandurangi, AK, Augmentation therapy with serial intravenous ketamine over 18 months in a patient with treatment resistant depression. Clin Neuropharmacol 38 (2015), 212–216.
    • (2015) Clin Neuropharmacol , vol.38 , pp. 212-216
    • Hassamal, S.1    Spivey, M.2    Pandurangi, A.K.3
  • 34
    • 85040151322 scopus 로고    scopus 로고
    • Ketamine (INN). Update review report. Agenda Item 6.1. Expert Committee on Drug Dependence, Thirty-seventh Meeting 2015
    • (accessed July 26, 2016).
    • WHO. Ketamine (INN). Update review report. Agenda Item 6.1. Expert Committee on Drug Dependence, Thirty-seventh Meeting 2015. http://www.who.int/medicines/access/controlledsubstances/6_1_Ketamine_Update_Review.pdf (accessed July 26, 2016).
  • 35
    • 84884218593 scopus 로고    scopus 로고
    • Ketamine as a new treatment for depression: a review of its efficacy and adverse effects
    • Katalinic, N, Lai, R, Somogyi, A, Mitchell, PB, Glue, P, Loo, CK, Ketamine as a new treatment for depression: a review of its efficacy and adverse effects. Aust N Z J Psychiatry 47 (2013), 710–727.
    • (2013) Aust N Z J Psychiatry , vol.47 , pp. 710-727
    • Katalinic, N.1    Lai, R.2    Somogyi, A.3    Mitchell, P.B.4    Glue, P.5    Loo, C.K.6
  • 36
    • 83355169638 scopus 로고    scopus 로고
    • Ketamine use: a review
    • Morgan, CJ, Curran, HV, Independent Scientific Committee on D. Ketamine use: a review. Addiction 107 (2012), 27–38.
    • (2012) Addiction , vol.107 , pp. 27-38
    • Morgan, C.J.1    Curran, H.V.2
  • 37
    • 85040147305 scopus 로고    scopus 로고
    • Ketamine offered to patients with depression in take-home, DIY packs by controversial clinic
    • (accessed Jan 10, 2017).
    • Worthington, E, Ketamine offered to patients with depression in take-home, DIY packs by controversial clinic. ABC News, May 30, 2015 http://www.abc.net.au/news/2015-05-30/ketamine-offered-to-patients-with-depression-in-take-home-packs/6508232 (accessed Jan 10, 2017).
    • (2015) ABC News
    • Worthington, E.1
  • 38
    • 85040146704 scopus 로고    scopus 로고
    • Medical clinics promote ketamine injections as treatment for depression
    • (accessed Jan 10, 2017).
    • Kembrey, M, Medical clinics promote ketamine injections as treatment for depression. Sydney Morning Herald, Feb 18, 2015 http://www.smh.com.au/nsw/medical-clinics-promote-ketamine-injections-as-treatment-for-depression-20150217-13h51o.html (accessed Jan 10, 2017).
    • (2015) Sydney Morning Herald
    • Kembrey, M.1
  • 39
    • 85040151209 scopus 로고    scopus 로고
    • Could ketamine become the next great depression drug?
    • (accessed Jan 12, 2017).
    • Bella, T, Could ketamine become the next great depression drug?. Aljazeera America, Feb 12, 2015 http://america.aljazeera.com/watch/shows/america-tonight/articles/2015/2/12/Ketamine.html (accessed Jan 12, 2017).
    • (2015) Aljazeera America
    • Bella, T.1
  • 40
    • 84954134987 scopus 로고    scopus 로고
    • Is off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications
    • Zhang, MW, Harris, KM, Ho, RC, Is off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications. BMC Medical Ethics, 17, 2016, 4.
    • (2016) BMC Medical Ethics , vol.17 , pp. 4
    • Zhang, M.W.1    Harris, K.M.2    Ho, R.C.3
  • 42
    • 34547626058 scopus 로고    scopus 로고
    • Systematic reviews of adverse effects: framework for a structured approach
    • Loke, YK, Price, D, Herxheimer, A, Cochrane Adverse Effects Methods Group. Systematic reviews of adverse effects: framework for a structured approach. BMC Med Res Methodol, 7, 2007, 32.
    • (2007) BMC Med Res Methodol , vol.7 , pp. 32
    • Loke, Y.K.1    Price, D.2    Herxheimer, A.3
  • 43
    • 0036289697 scopus 로고    scopus 로고
    • Small-dose ketamine improves the postoperative state of depressed patients
    • Kudoh, A, Takahira, Y, Katagai, H, Takazawa, T, Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg 95 (2002), 114–118.
    • (2002) Anesth Analg , vol.95 , pp. 114-118
    • Kudoh, A.1    Takahira, Y.2    Katagai, H.3    Takazawa, T.4
  • 44
    • 33746896935 scopus 로고    scopus 로고
    • A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression
    • Zarate, CA Jr, Singh, JB, Carlson, PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63 (2006), 856–864.
    • (2006) Arch Gen Psychiatry , vol.63 , pp. 856-864
    • Zarate, C.A.1    Singh, J.B.2    Carlson, P.J.3
  • 45
    • 77955891255 scopus 로고    scopus 로고
    • A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression
    • Diazgranados, N, Ibrahim, L, Brutsche, NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67 (2010), 793–802.
    • (2010) Arch Gen Psychiatry , vol.67 , pp. 793-802
    • Diazgranados, N.1    Ibrahim, L.2    Brutsche, N.E.3
  • 46
    • 84861099072 scopus 로고    scopus 로고
    • Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial
    • Zarate, CA Jr, Brutsche, NE, Ibrahim, L, et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 71 (2012), 939–946.
    • (2012) Biol Psychiatry , vol.71 , pp. 939-946
    • Zarate, C.A.1    Brutsche, N.E.2    Ibrahim, L.3
  • 47
    • 84885214350 scopus 로고    scopus 로고
    • Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial
    • Murrough, JW, Iosifescu, DV, Chang, LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 170 (2013), 1134–1142.
    • (2013) Am J Psychiatry , vol.170 , pp. 1134-1142
    • Murrough, J.W.1    Iosifescu, D.V.2    Chang, L.C.3
  • 48
    • 84925457771 scopus 로고    scopus 로고
    • Efficacy and safety of intravenous esketamine in patients with treatment-resistant depression: a double-blind, double-randomization, placebo controlled phase 2a study
    • Singh, J, Fedgchin, M, Daly, E, et al. Efficacy and safety of intravenous esketamine in patients with treatment-resistant depression: a double-blind, double-randomization, placebo controlled phase 2a study. Neuropsychopharmacology 38 (2013), s369–s370.
    • (2013) Neuropsychopharmacology , vol.38 , pp. s369-s370
    • Singh, J.1    Fedgchin, M.2    Daly, E.3
  • 49
    • 84880555463 scopus 로고    scopus 로고
    • Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression
    • Sos, P, Klirova, M, Novak, T, Kohutova, B, Horacek, J, Palenicek, T, Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinol Lett 34 (2013), 287–293.
    • (2013) Neuro Endocrinol Lett , vol.34 , pp. 287-293
    • Sos, P.1    Klirova, M.2    Novak, T.3    Kohutova, B.4    Horacek, J.5    Palenicek, T.6
  • 50
    • 84893715460 scopus 로고    scopus 로고
    • Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder
    • Ghasemi, M, Kazemi, MH, Yoosefi, A, et al. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry Res 215 (2014), 355–361.
    • (2014) Psychiatry Res , vol.215 , pp. 355-361
    • Ghasemi, M.1    Kazemi, M.H.2    Yoosefi, A.3
  • 51
    • 84907260750 scopus 로고    scopus 로고
    • Pilot dose-response trial of i.v. ketamine in treatment-resistant depression
    • Lai, R, Katalinic, N, Glue, P, et al. Pilot dose-response trial of i.v. ketamine in treatment-resistant depression. World J Biol Psychiatry 15 (2014), 579–584.
    • (2014) World J Biol Psychiatry , vol.15 , pp. 579-584
    • Lai, R.1    Katalinic, N.2    Glue, P.3
  • 52
    • 84919398586 scopus 로고    scopus 로고
    • A randomized controlled trial of intranasal ketamine in major depressive disorder
    • Lapidus, KA, Levitch, CF, Perez, AM, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry 76 (2014), 970–976.
    • (2014) Biol Psychiatry , vol.76 , pp. 970-976
    • Lapidus, K.A.1    Levitch, C.F.2    Perez, A.M.3
  • 53
    • 84945478974 scopus 로고    scopus 로고
    • Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial
    • Murrough, J, Soleimani, L, DeWilde, K, et al. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med 45 (2015), 3571–3580.
    • (2015) Psychol Med , vol.45 , pp. 3571-3580
    • Murrough, J.1    Soleimani, L.2    DeWilde, K.3
  • 54
    • 84961160408 scopus 로고    scopus 로고
    • Single I.V. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study
    • Hu, Y, Xiang, Y, Fang, J, et al. Single I.V. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Psychol Med 46 (2015), 623–635.
    • (2015) Psychol Med , vol.46 , pp. 623-635
    • Hu, Y.1    Xiang, Y.2    Fang, J.3
  • 55
    • 84959190094 scopus 로고    scopus 로고
    • Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: a pilot randomised controlled trial
    • Lenze, EJ, Farber, NB, Kharasch, E, et al. Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: a pilot randomised controlled trial. World J Biol Psychiatry 17 (2016), 230–238.
    • (2016) World J Biol Psychiatry , vol.17 , pp. 230-238
    • Lenze, E.J.1    Farber, N.B.2    Kharasch, E.3
  • 56
    • 84958236573 scopus 로고    scopus 로고
    • The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: a randomized controlled study
    • Li, C-T, Chen, M-H, Lin, W-C, et al. The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: a randomized controlled study. Hum Brain Mapp 37 (2016), 1080–1090.
    • (2016) Hum Brain Mapp , vol.37 , pp. 1080-1090
    • Li, C.-T.1    Chen, M.-H.2    Lin, W.-C.3
  • 57
    • 84973610912 scopus 로고    scopus 로고
    • Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression
    • Loo, C, Galvez, V, O'Keefe, E, et al. Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatr Scand 134 (2016), 48–56.
    • (2016) Acta Psychiatr Scand , vol.134 , pp. 48-56
    • Loo, C.1    Galvez, V.2    O'Keefe, E.3
  • 58
    • 84991272304 scopus 로고    scopus 로고
    • A double-blind, randomized, placebo-controlled, parallel group, dose frequency study of intravenous ketamine in patients with treatment-resistant depression
    • Singh, J, Fedgchin, M, Daly, E, et al. A double-blind, randomized, placebo-controlled, parallel group, dose frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry 173 (2016), 816–826.
    • (2016) Am J Psychiatry , vol.173 , pp. 816-826
    • Singh, J.1    Fedgchin, M.2    Daly, E.3
  • 59
    • 84975144373 scopus 로고    scopus 로고
    • Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: a double-blind, randomized, controlled trial
    • Jafarinia, M, Afarideh, M, Tafakhori, A, et al. Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: a double-blind, randomized, controlled trial. J Affect Disord 204 (2016), 1–8.
    • (2016) J Affect Disord , vol.204 , pp. 1-8
    • Jafarinia, M.1    Afarideh, M.2    Tafakhori, A.3
  • 60
    • 84964577685 scopus 로고    scopus 로고
    • Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate
    • Downey, D, Dutta, A, McKie, S, et al. Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate. Eur Neuropsychopharmacol 26 (2016), 994–1003.
    • (2016) Eur Neuropsychopharmacol , vol.26 , pp. 994-1003
    • Downey, D.1    Dutta, A.2    McKie, S.3
  • 61
    • 85040139996 scopus 로고    scopus 로고
    • Pilot randomized-controlled trial of titrated subcutaneous ketamine in older patients with treatment resistant depression. Am J Geriatric Psychiatry (in press).
    • George D, Galvez V, Martin D, et al. Pilot randomized-controlled trial of titrated subcutaneous ketamine in older patients with treatment resistant depression. Am J Geriatric Psychiatry (in press).
    • George, D.1    Galvez, V.2    Martin, D.3
  • 62
    • 58049211903 scopus 로고    scopus 로고
    • Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist
    • Phelps, LE, Brustch, N, Moral, JR, Luckenbaugh, D, Manji, H, Zarate, C, Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry 65 (2009), 181–184.
    • (2009) Biol Psychiatry , vol.65 , pp. 181-184
    • Phelps, L.E.1    Brustch, N.2    Moral, J.R.3    Luckenbaugh, D.4    Manji, H.5    Zarate, C.6
  • 63
    • 77949625234 scopus 로고    scopus 로고
    • Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial
    • Mathew, SJ, Murrough, JW, aan het Rot, M, Collins, KA, Reich, DL, Charney, DS, Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol 13 (2010), 71–82.
    • (2010) Int J Neuropsychopharmacol , vol.13 , pp. 71-82
    • Mathew, S.J.1    Murrough, J.W.2    aan het Rot, M.3    Collins, K.A.4    Reich, D.L.5    Charney, D.S.6
  • 64
    • 79955993457 scopus 로고    scopus 로고
    • Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression
    • Ibrahim, L, Diazgranados, N, Luckenbaugh, DA, et al. Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry 35 (2011), 1155–1159.
    • (2011) Prog Neuropsychopharmacol Biol Psychiatry , vol.35 , pp. 1155-1159
    • Ibrahim, L.1    Diazgranados, N.2    Luckenbaugh, D.A.3
  • 65
    • 80053025475 scopus 로고    scopus 로고
    • A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department
    • Larkin, GL, Beautrais, AL, A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol 14 (2011), 1127–1131.
    • (2011) Int J Neuropsychopharmacol , vol.14 , pp. 1127-1131
    • Larkin, G.L.1    Beautrais, A.L.2
  • 66
    • 78751701060 scopus 로고    scopus 로고
    • The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS
    • Valentine, GW, Mason, GF, Gomez, R, et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res 191 (2011), 122–127.
    • (2011) Psychiatry Res , vol.191 , pp. 122-127
    • Valentine, G.W.1    Mason, G.F.2    Gomez, R.3
  • 67
    • 84859777474 scopus 로고    scopus 로고
    • Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study
    • Ibrahim, L, Diazgranados, N, Franco-Chaves, J, et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 37 (2012), 1526–1533.
    • (2012) Neuropsychopharmacology , vol.37 , pp. 1526-1533
    • Ibrahim, L.1    Diazgranados, N.2    Franco-Chaves, J.3
  • 68
    • 84864286398 scopus 로고    scopus 로고
    • Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression
    • Zarate, CA Jr, Brutsche, N, Laje, G, et al. Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry 72 (2012), 331–338.
    • (2012) Biol Psychiatry , vol.72 , pp. 331-338
    • Zarate, C.A.1    Brutsche, N.2    Laje, G.3
  • 69
    • 84930416474 scopus 로고    scopus 로고
    • A single infusion of ketamine improves depression scores in patients with anxious bipolar depression
    • Ionescu, DF, Luckenbaugh, DA, Niciu, MJ, Richards, EM, Zarate, CA Jr, A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. Bipolar Disord 17 (2015), 438–443.
    • (2015) Bipolar Disord , vol.17 , pp. 438-443
    • Ionescu, D.F.1    Luckenbaugh, D.A.2    Niciu, M.J.3    Richards, E.M.4    Zarate, C.A.5
  • 70
    • 84932626621 scopus 로고    scopus 로고
    • Single-dose ketamine followed by daily D-cycloserine in treatment-resistant bipolar depression
    • Kantrowitz, JT, Halberstam, B, Gangwisch, J, Single-dose ketamine followed by daily D-cycloserine in treatment-resistant bipolar depression. J Clin Psychiatry 76 (2015), 737–738.
    • (2015) J Clin Psychiatry , vol.76 , pp. 737-738
    • Kantrowitz, J.T.1    Halberstam, B.2    Gangwisch, J.3
  • 71
    • 77954950428 scopus 로고    scopus 로고
    • Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care
    • Irwin, SA, Iglewicz, A, Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. J Palliat Med 13 (2010), 903–908.
    • (2010) J Palliat Med , vol.13 , pp. 903-908
    • Irwin, S.A.1    Iglewicz, A.2
  • 72
    • 84879407498 scopus 로고    scopus 로고
    • Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder
    • Niciu, MJ, Grunschel, BD, Corlett, PR, Pittenger, C, Bloch, MH, Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder. J Psychopharmacol 27 (2013), 651–654.
    • (2013) J Psychopharmacol , vol.27 , pp. 651-654
    • Niciu, M.J.1    Grunschel, B.D.2    Corlett, P.R.3    Pittenger, C.4    Bloch, M.H.5
  • 73
    • 84876440651 scopus 로고    scopus 로고
    • Effects of ketamine on major depressive disorder in a patient with posttraumatic stress disorder
    • Womble, AL, Effects of ketamine on major depressive disorder in a patient with posttraumatic stress disorder. AANA J 81 (2013), 118–119.
    • (2013) AANA J , vol.81 , pp. 118-119
    • Womble, A.L.1
  • 74
    • 84903707853 scopus 로고    scopus 로고
    • Rapid resolution of suicidal behavior and depression with single low-dose ketamine intravenous push even after 6 months of follow-up
    • Aligeti, S, Quinones, M, Salazar, R, Rapid resolution of suicidal behavior and depression with single low-dose ketamine intravenous push even after 6 months of follow-up. J Clin Psychopharmacol 34 (2014), 533–535.
    • (2014) J Clin Psychopharmacol , vol.34 , pp. 533-535
    • Aligeti, S.1    Quinones, M.2    Salazar, R.3
  • 75
    • 85065112137 scopus 로고    scopus 로고
    • Experience integrating ketamine into the healthcare system: outpatient and inpatient treatment of post-partum depression, suicidal ideation and comorbid chronic pain-mood disorders
    • Quinones, M, Diazgranados, N, Eckmann, M, Ramamurthy, S, Bowden, C, Delgado, PL, Experience integrating ketamine into the healthcare system: outpatient and inpatient treatment of post-partum depression, suicidal ideation and comorbid chronic pain-mood disorders. Neuropsychopharmacology 38 (2012), s442–s443.
    • (2012) Neuropsychopharmacology , vol.38 , pp. s442-s443
    • Quinones, M.1    Diazgranados, N.2    Eckmann, M.3    Ramamurthy, S.4    Bowden, C.5    Delgado, P.L.6
  • 76
    • 84937520979 scopus 로고    scopus 로고
    • Ketamine for the treatment of depression in patients receiving hospice care: a retrospective medical record review of thirty-one cases
    • Iglewicz, A, Morrison, K, Nelesen, RA, et al. Ketamine for the treatment of depression in patients receiving hospice care: a retrospective medical record review of thirty-one cases. Psychosomatics 56 (2015), 329–337.
    • (2015) Psychosomatics , vol.56 , pp. 329-337
    • Iglewicz, A.1    Morrison, K.2    Nelesen, R.A.3
  • 78
    • 84925487684 scopus 로고    scopus 로고
    • Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial
    • Murrough, JW, Burdick, KE, Levitch, CF, et al. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacology 40 (2015), 1084–1090.
    • (2015) Neuropsychopharmacology , vol.40 , pp. 1084-1090
    • Murrough, J.W.1    Burdick, K.E.2    Levitch, C.F.3
  • 79
    • 84892805424 scopus 로고    scopus 로고
    • Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response
    • Murrough, JW, Wan, L-B, Iacoviello, B, et al. Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. Psychopharmacology 231 (2014), 481–488.
    • (2014) Psychopharmacology , vol.231 , pp. 481-488
    • Murrough, J.W.1    Wan, L.-B.2    Iacoviello, B.3
  • 80
    • 84922041650 scopus 로고    scopus 로고
    • Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine
    • Ionescu, DF, Luckenbaugh, DA, Niciu, MJ, et al. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J Clin Psychiatry 75 (2014), e932–e938.
    • (2014) J Clin Psychiatry , vol.75 , pp. e932-e938
    • Ionescu, D.F.1    Luckenbaugh, D.A.2    Niciu, M.J.3
  • 81
    • 84915745090 scopus 로고    scopus 로고
    • Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance
    • Sahu, R, Yadav, R, Prasad, P, Roy, A, Chandrakar, S, Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance. SpringerPlus, 3, 2014, 695.
    • (2014) SpringerPlus , vol.3 , pp. 695
    • Sahu, R.1    Yadav, R.2    Prasad, P.3    Roy, A.4    Chandrakar, S.5
  • 82
    • 45849119038 scopus 로고    scopus 로고
    • Pharmacovigilance: methods, recent developments and future perspective
    • Harmark, L, Van Grootheest, A, Pharmacovigilance: methods, recent developments and future perspective. Eur J Clin Pharmacol 64 (2008), 743–752.
    • (2008) Eur J Clin Pharmacol , vol.64 , pp. 743-752
    • Harmark, L.1    Van Grootheest, A.2
  • 83
    • 85040145707 scopus 로고    scopus 로고
    • Fact file on ketamine 2016
    • (accessed July 9, 2016).
    • WHO. Fact file on ketamine 2016. http://www.who.int/medicines/news/20160309_FactFile_Ketamine.pdf, July 9, 2016 (accessed July 9, 2016).
    • (2016)
  • 84
    • 34247580765 scopus 로고    scopus 로고
    • Ketamine-associated ulcerative cystitis: a new clinical entity
    • Shahani, R, Streutker, C, Dickson, B, Stewart, RJ, Ketamine-associated ulcerative cystitis: a new clinical entity. Urology 69 (2007), 810–812.
    • (2007) Urology , vol.69 , pp. 810-812
    • Shahani, R.1    Streutker, C.2    Dickson, B.3    Stewart, R.J.4
  • 85
    • 80052744525 scopus 로고    scopus 로고
    • The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use
    • Kalsi, SS, Wood, DM, Dargan, PI, The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerg Health Threats J, 4, 2011, 7107.
    • (2011) Emerg Health Threats J , vol.4 , pp. 7107
    • Kalsi, S.S.1    Wood, D.M.2    Dargan, P.I.3
  • 86
    • 77957654863 scopus 로고    scopus 로고
    • Ketamine-associated ulcerative cystitis: a case report and literature review
    • Ho, CC, Pezhman, H, Praveen, S, Goh, E, Lee, B, Zulkifli, M, Ketamine-associated ulcerative cystitis: a case report and literature review. Malays J Med Sci 17 (2009), 61–65.
    • (2009) Malays J Med Sci , vol.17 , pp. 61-65
    • Ho, C.C.1    Pezhman, H.2    Praveen, S.3    Goh, E.4    Lee, B.5    Zulkifli, M.6
  • 87
    • 78650437364 scopus 로고    scopus 로고
    • Ketamine induced vesicopathy: a literature review
    • Middela, S, Pearce, I, Ketamine induced vesicopathy: a literature review. Int J Clin Pract, 65, 2010, 27.
    • (2010) Int J Clin Pract , vol.65 , pp. 27
    • Middela, S.1    Pearce, I.2
  • 89
    • 44649184847 scopus 로고    scopus 로고
    • A pediatric case of ketamine-associated cystitis (Letter-to-the-Editor RE: Shahani R, Streutker C, Dickson B, et al: Ketamine-associated ulcerative cystitis: a new clinical entity. Urology 2007; 69: 810–12)
    • Gregoire, MC, MacLellan, DL, Finley, GA, A pediatric case of ketamine-associated cystitis (Letter-to-the-Editor RE: Shahani R, Streutker C, Dickson B, et al: Ketamine-associated ulcerative cystitis: a new clinical entity. Urology 2007; 69: 810–12). Urology 71 (2008), 1232–1233.
    • (2008) Urology , vol.71 , pp. 1232-1233
    • Gregoire, M.C.1    MacLellan, D.L.2    Finley, G.A.3
  • 90
    • 71049185534 scopus 로고    scopus 로고
    • Can ketamine prescribed for pain cause damage to the urinary tract?
    • Storr, TM, Quibell, R, Can ketamine prescribed for pain cause damage to the urinary tract?. Palliat Med 23 (2009), 670–672.
    • (2009) Palliat Med , vol.23 , pp. 670-672
    • Storr, T.M.1    Quibell, R.2
  • 91
    • 77954660031 scopus 로고    scopus 로고
    • Wherefore ketamine?
    • Persson, J, Wherefore ketamine?. Curr Opin Anaesthesiol 23 (2010), 455–460.
    • (2010) Curr Opin Anaesthesiol , vol.23 , pp. 455-460
    • Persson, J.1
  • 92
    • 84870907061 scopus 로고    scopus 로고
    • The prevalence and natural history of urinary symptoms among recreational ketamine users
    • Winstock, AR, Mitcheson, L, Gillatt, DA, Cottrell, AM, The prevalence and natural history of urinary symptoms among recreational ketamine users. BJU Int 110 (2012), 1762–1766.
    • (2012) BJU Int , vol.110 , pp. 1762-1766
    • Winstock, A.R.1    Mitcheson, L.2    Gillatt, D.A.3    Cottrell, A.M.4
  • 93
    • 53849124821 scopus 로고    scopus 로고
    • The destruction of the lower urinary tract by ketamine abuse: a new syndrome?
    • Chu, PS, Ma, WK, Wong, SC, et al. The destruction of the lower urinary tract by ketamine abuse: a new syndrome?. BJU Int 102 (2008), 1616–1622.
    • (2008) BJU Int , vol.102 , pp. 1616-1622
    • Chu, P.S.1    Ma, W.K.2    Wong, S.C.3
  • 94
    • 79957868300 scopus 로고    scopus 로고
    • Recreational ketamine: from pleasure to pain
    • Wood, D, Cottrell, A, Baker, SC, et al. Recreational ketamine: from pleasure to pain. BJU Int 107 (2011), 1881–1884.
    • (2011) BJU Int , vol.107 , pp. 1881-1884
    • Wood, D.1    Cottrell, A.2    Baker, S.C.3
  • 95
    • 84961219147 scopus 로고    scopus 로고
    • Ketamine-induced apoptosis in normal human urothelial cells
    • Baker, SC, Shabir, S, Georgopoulos, N, Southgate, J, Ketamine-induced apoptosis in normal human urothelial cells. Am J Pathol 186 (2016), 1267–1277.
    • (2016) Am J Pathol , vol.186 , pp. 1267-1277
    • Baker, S.C.1    Shabir, S.2    Georgopoulos, N.3    Southgate, J.4
  • 96
    • 80052920605 scopus 로고    scopus 로고
    • Urinary symptoms and impaired quality of life in female ketamine users: persistence after cessation of use
    • Cheung, RY, Chan, SS, Lee, JH, Pang, AW, Choy, KW, Chung, TK, Urinary symptoms and impaired quality of life in female ketamine users: persistence after cessation of use. Hong Kong Med J 17 (2011), 267–273.
    • (2011) Hong Kong Med J , vol.17 , pp. 267-273
    • Cheung, R.Y.1    Chan, S.S.2    Lee, J.H.3    Pang, A.W.4    Choy, K.W.5    Chung, T.K.6
  • 97
    • 80051801177 scopus 로고    scopus 로고
    • Drug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients: a report of 3 cases
    • Noppers, IM, Niesters, M, Aarts, LP, et al. Drug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients: a report of 3 cases. Pain 152 (2011), 2173–2178.
    • (2011) Pain , vol.152 , pp. 2173-2178
    • Noppers, I.M.1    Niesters, M.2    Aarts, L.P.3
  • 98
    • 80052744525 scopus 로고    scopus 로고
    • The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use
    • Kalsi, SS, Wood, DM, Dargan, PI, The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerg Health Threats J, 4, 2011, 7107.
    • (2011) Emerg Health Threats J , vol.4 , pp. 7107
    • Kalsi, S.S.1    Wood, D.M.2    Dargan, P.I.3
  • 99
    • 84863692226 scopus 로고    scopus 로고
    • Ketamine for chronic noncancer pain: concerns regarding toxicity
    • Bell, RF, Ketamine for chronic noncancer pain: concerns regarding toxicity. Curr Opin Support Palliat Care 6 (2012), 183–187.
    • (2012) Curr Opin Support Palliat Care , vol.6 , pp. 183-187
    • Bell, R.F.1
  • 100
    • 80051801062 scopus 로고    scopus 로고
    • Ketamine hepato-toxicity in chronic pain management: another example of unexpected toxicity or a predicted result from previous clinical and pre-clinical data?
    • Sear, JW, Ketamine hepato-toxicity in chronic pain management: another example of unexpected toxicity or a predicted result from previous clinical and pre-clinical data?. Pain 152 (2011), 1946–1947.
    • (2011) Pain , vol.152 , pp. 1946-1947
    • Sear, J.W.1
  • 101
    • 0026528194 scopus 로고
    • Location of enkephalinase and functional effects of [Leu5]enkephalin and inhibition of enkephalinase in the feline main pancreatic and bile duct sphincters
    • Thune, A, Jivegard, L, Pollard, H, Moreau, J, Schwartz, JC, Svanvik, J, Location of enkephalinase and functional effects of [Leu5]enkephalin and inhibition of enkephalinase in the feline main pancreatic and bile duct sphincters. Clin Sci (Lond) 82 (1992), 169–173.
    • (1992) Clin Sci (Lond) , vol.82 , pp. 169-173
    • Thune, A.1    Jivegard, L.2    Pollard, H.3    Moreau, J.4    Schwartz, J.C.5    Svanvik, J.6
  • 102
    • 48549085136 scopus 로고    scopus 로고
    • Prospective evaluation of adjunctive ketamine on sphincter of Oddi motility in humans
    • Varadarajulu, S, Tamhane, A, Wilcox, CM, Prospective evaluation of adjunctive ketamine on sphincter of Oddi motility in humans. J Gastroenterol Hepatol 23 (2008), e405–e409.
    • (2008) J Gastroenterol Hepatol , vol.23 , pp. e405-e409
    • Varadarajulu, S.1    Tamhane, A.2    Wilcox, C.M.3
  • 103
    • 79958281271 scopus 로고    scopus 로고
    • Cholestasis and biliary dilatation associated with chronic ketamine abuse: a case series
    • Lo, RS, Krishnamoorthy, R, Freeman, JG, Austin, AS, Cholestasis and biliary dilatation associated with chronic ketamine abuse: a case series. Singapore Med J 52 (2011), e52–e55.
    • (2011) Singapore Med J , vol.52 , pp. e52-e55
    • Lo, R.S.1    Krishnamoorthy, R.2    Freeman, J.G.3    Austin, A.S.4
  • 104
    • 32144440105 scopus 로고    scopus 로고
    • Semantic priming after ketamine acutely in healthy volunteers and following chronic self-administration in substance users
    • Morgan, CJ, Rossell, SL, Pepper, F, et al. Semantic priming after ketamine acutely in healthy volunteers and following chronic self-administration in substance users. Biol Psychiatry 59 (2006), 265–272.
    • (2006) Biol Psychiatry , vol.59 , pp. 265-272
    • Morgan, C.J.1    Rossell, S.L.2    Pepper, F.3
  • 105
    • 0029095652 scopus 로고
    • Central nervous system effects of subdissociative doses of (S)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers
    • Hartvig, P, Valtysson, J, Lindner, KJ, et al. Central nervous system effects of subdissociative doses of (S)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers. Clin Pharmacol Ther 58 (1995), 165–173.
    • (1995) Clin Pharmacol Ther , vol.58 , pp. 165-173
    • Hartvig, P.1    Valtysson, J.2    Lindner, K.J.3
  • 106
    • 0028323167 scopus 로고
    • Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses
    • Krystal, JH, Karper, LP, Seibyl, JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51 (1994), 199–214.
    • (1994) Arch Gen Psychiatry , vol.51 , pp. 199-214
    • Krystal, J.H.1    Karper, L.P.2    Seibyl, J.P.3
  • 107
    • 0029927565 scopus 로고    scopus 로고
    • NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers
    • Malhotra, AK, Pinals, DA, Weingartner, H, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14 (1996), 301–307.
    • (1996) Neuropsychopharmacology , vol.14 , pp. 301-307
    • Malhotra, A.K.1    Pinals, D.A.2    Weingartner, H.3
  • 108
    • 28444468469 scopus 로고    scopus 로고
    • Altered prefrontal dopaminergic function in chronic recreational ketamine users
    • Narendran, R, Frankle, WG, Keefe, R, et al. Altered prefrontal dopaminergic function in chronic recreational ketamine users. Am J Psychiatry 162 (2005), 2352–2359.
    • (2005) Am J Psychiatry , vol.162 , pp. 2352-2359
    • Narendran, R.1    Frankle, W.G.2    Keefe, R.3
  • 109
    • 34548294171 scopus 로고    scopus 로고
    • The neurocognitive effects of 5 day anesthetic ketamine for the treatment of refractory complex regional pain syndrome
    • Koffler, SP, Hampstead, BM, Irani, F, et al. The neurocognitive effects of 5 day anesthetic ketamine for the treatment of refractory complex regional pain syndrome. Arch Clin Neuropsychol 22 (2007), 719–729.
    • (2007) Arch Clin Neuropsychol , vol.22 , pp. 719-729
    • Koffler, S.P.1    Hampstead, B.M.2    Irani, F.3
  • 110
    • 0004975091 scopus 로고
    • WHO model prescribing information: drugs used in anaesthesia
    • (accessed Feb 1, 2017).
    • WHO. WHO model prescribing information: drugs used in anaesthesia. http://apps.who.int/medicinedocs/en/d/Jh2929e/4.html, 1989 (accessed Feb 1, 2017).
    • (1989)
  • 111
    • 84893124516 scopus 로고    scopus 로고
    • Ketamine for chronic pain: Risks and benefits
    • Niesters, M, Martini, C, Dahan, A, Ketamine for chronic pain: Risks and benefits. Br J Clin Pharmacol 77 (2014), 357–367.
    • (2014) Br J Clin Pharmacol , vol.77 , pp. 357-367
    • Niesters, M.1    Martini, C.2    Dahan, A.3
  • 112
    • 58749114718 scopus 로고    scopus 로고
    • Ketamine for chronic non-cancer pain
    • Bell, R, Ketamine for chronic non-cancer pain. Pain 141 (2009), 210–214.
    • (2009) Pain , vol.141 , pp. 210-214
    • Bell, R.1
  • 113
    • 85040146616 scopus 로고    scopus 로고
    • Anaesthetic apocalypse. Ketamine part 2: addictive psychedelic
    • Jansen, K, Anaesthetic apocalypse. Ketamine part 2: addictive psychedelic. Druglink(March/April), 2000, 18–21.
    • (2000) Druglink , Issue.March/April , pp. 18-21
    • Jansen, K.1
  • 114
    • 0026496669 scopus 로고
    • Tolerance to the cataleptic effect of the N-methyl-D-aspartate (NMDA) receptor antagonists in pigeons: cross-tolerance between PCP-like compounds and competitive NMDA antagonists
    • Lu, Y, France, CP, Woods, JH, Tolerance to the cataleptic effect of the N-methyl-D-aspartate (NMDA) receptor antagonists in pigeons: cross-tolerance between PCP-like compounds and competitive NMDA antagonists. J Pharmacol Exp Ther 263 (1992), 499–504.
    • (1992) J Pharmacol Exp Ther , vol.263 , pp. 499-504
    • Lu, Y.1    France, C.P.2    Woods, J.H.3
  • 116
    • 77950473226 scopus 로고    scopus 로고
    • A case of ketamine dependence
    • (in Polish).
    • Blachut, M, Solowiow, K, Janus, A, et al. A case of ketamine dependence. Psychiatr Pol 43 (2009), 593–609 (in Polish).
    • (2009) Psychiatr Pol , vol.43 , pp. 593-609
    • Blachut, M.1    Solowiow, K.2    Janus, A.3
  • 117
    • 0036756573 scopus 로고    scopus 로고
    • Ketamine as a preferred substance of abuse
    • Bobo, WV, Miller, SC, Ketamine as a preferred substance of abuse. Am J Addict 11 (2002), 332–334.
    • (2002) Am J Addict , vol.11 , pp. 332-334
    • Bobo, W.V.1    Miller, S.C.2
  • 118
    • 33745771302 scopus 로고    scopus 로고
    • A case of ketamine dependence with discontinuation symptoms
    • Critchlow, DG, A case of ketamine dependence with discontinuation symptoms. Addiction 101 (2006), 1212–1213.
    • (2006) Addiction , vol.101 , pp. 1212-1213
    • Critchlow, D.G.1
  • 119
    • 0023406003 scopus 로고
    • A case of ketamine dependence
    • (in Polish).
    • Florkowski, A, Ferfecki, L, A case of ketamine dependence. Psychiatr Pol 21 (1987), 434–435 (in Polish).
    • (1987) Psychiatr Pol , vol.21 , pp. 434-435
    • Florkowski, A.1    Ferfecki, L.2
  • 120
    • 0037256772 scopus 로고    scopus 로고
    • Ketamine associated psychedelic effects and dependence
    • Lim, DK, Ketamine associated psychedelic effects and dependence. Singapore Med J 44 (2003), 31–34.
    • (2003) Singapore Med J , vol.44 , pp. 31-34
    • Lim, D.K.1
  • 122
    • 84944351815 scopus 로고    scopus 로고
    • Long-term ketamine self-injections in major depressive disorder: focus on tolerance in ketamine's antidepressant response and the development of ketamine addiction
    • Bonnet, U, Long-term ketamine self-injections in major depressive disorder: focus on tolerance in ketamine's antidepressant response and the development of ketamine addiction. J Psychoactive Drugs 47 (2015), 276–285.
    • (2015) J Psychoactive Drugs , vol.47 , pp. 276-285
    • Bonnet, U.1
  • 124
    • 0035828451 scopus 로고    scopus 로고
    • Assessment of therapeutic safety in systematic reviews: literature review
    • Ernst, E, Pittler, MH, Assessment of therapeutic safety in systematic reviews: literature review. BMJ, 323, 2001, 546.
    • (2001) BMJ , vol.323 , pp. 546
    • Ernst, E.1    Pittler, M.H.2
  • 125
    • 20544439606 scopus 로고    scopus 로고
    • Challenges in systematic reviews that assess treatment harms
    • Chou, R, Helfand, M, Challenges in systematic reviews that assess treatment harms. Ann Intern Med 142 (2005), 1090–1099.
    • (2005) Ann Intern Med , vol.142 , pp. 1090-1099
    • Chou, R.1    Helfand, M.2
  • 126
    • 84872792216 scopus 로고    scopus 로고
    • Some improvements are apparent in identifying adverse effects in systematic reviews from 1994 to 2011
    • Golder, S, Loke, YK, Zorzela, L, Some improvements are apparent in identifying adverse effects in systematic reviews from 1994 to 2011. J Clin Epidemiol 66 (2013), 253–260.
    • (2013) J Clin Epidemiol , vol.66 , pp. 253-260
    • Golder, S.1    Loke, Y.K.2    Zorzela, L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.